What is the prevalence of Doose Syndrome?

TL;DR: Doose syndrome, also known as Myoclonic Atonic Epilepsy (MAE), is a rare pediatric epilepsy syndrome estimated to account for approximately 1% to 2% of all childhood epilepsies. While precise global prevalence figures are limited due to diagnostic complexity, it is considered a rare disease, typically manifesting in children between the ages of 7 months and 6 years.

How common is Doose syndrome?

Doose syndrome is classified as a rare neurological disorder. Because it is often misdiagnosed as other forms of childhood epilepsy, such as Lennox-Gastaut syndrome or benign myoclonic epilepsy in infancy, exact prevalence numbers are difficult to calculate. Current medical literature, including data from Orphanet, categorizes Doose syndrome as a rare condition, though it is one of the more frequently encountered epilepsy syndromes within pediatric neurology clinics. Within our own DiseaseMaps.org community, 65 individuals have identified as having Doose syndrome, providing a valuable, albeit non-clinical, real-world perspective on the prevalence and impact of this condition on families globally.

Does Doose syndrome affect males and females differently?

Clinical observations consistently indicate a gender-based difference in the prevalence of Doose syndrome. Research suggests that the condition is more common in males than in females, with a male-to-female ratio often reported as approximately 2:1. While the exact biological mechanism behind this gender disparity remains a subject of ongoing research, it is a well-documented clinical feature of the syndrome.

At what age does Doose syndrome typically begin?

Doose syndrome is strictly a pediatric-onset condition. The typical age of onset ranges from 7 months to 6 years, with the peak incidence occurring between ages 2 and 4. It is rare for the symptoms of Doose syndrome to present outside of this window. The onset is generally characterized by the sudden appearance of generalized tonic-clonic seizures or myoclonic-atonic seizures, which are the hallmark clinical features of the diagnosis.

Are there geographic or ethnic variations in the prevalence of Doose syndrome?

There is currently no robust clinical evidence to suggest that Doose syndrome is more prevalent in specific geographic regions or ethnic groups. Because Doose syndrome is a complex, likely polygenic condition, it appears to occur globally across all populations. The primary challenge in determining geographic distribution is not ethnicity, but rather access to specialized pediatric neurology care and advanced genetic testing, which can lead to under-reporting in underserved areas.

Why is accurate data on Doose syndrome prevalence difficult to obtain?

Several factors contribute to the difficulty in establishing precise statistics for Doose syndrome:

• Diagnostic Overlap: The clinical presentation of Doose syndrome can evolve, leading clinicians to initially misclassify the condition as other epilepsy syndromes.


• Evolution of Symptoms: Seizure types in Doose syndrome often change over time, which can obscure the initial diagnosis.


• Limited Registry Data: Unlike more common conditions, there are few comprehensive, global patient registries dedicated solely to tracking the incidence of this specific syndrome.


• Underdiagnosis: In many clinical settings, the lack of long-term video-EEG monitoring may prevent a definitive diagnosis of Doose syndrome.

Next steps

• Consult a pediatric epileptologist to discuss specialized diagnostic testing, such as long-term video-EEG.


• Connect with the 65 members of the DiseaseMaps.org community to share experiences and find peer-to-peer support.


• Inquire about current clinical trials or research studies regarding the genetic underpinnings of Doose syndrome through the NIH GARD portal.


• Maintain a detailed seizure diary to assist your neurologist in tracking the progression and response to treatments.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of a qualified healthcare provider with any questions regarding a medical condition.

References

• Orphanet (ORPHA: 308): Myoclonic-atonic epilepsy.


• NIH Genetic and Rare Diseases Information Center (GARD): Doose Syndrome.


• OMIM (Online Mendelian Inheritance in Man): Epilepsy with Myoclonic-Atonic Seizures (#607208).


• Epilepsy Foundation: Information on Childhood Epilepsy Syndromes.